Who is sponsoring NCT07130591?

NCT07130591 is sponsored by Izmir Democracy University.

What drugs are being tested in NCT07130591?

Interventions in NCT07130591: Cogniplat game platform, Control group.

What condition does NCT07130591 study?

NCT07130591 studies Mild Cognitive Impairment.

Is NCT07130591 still recruiting?

NCT07130591 is currently completed. Last updated 26 August 2025.

Last reviewed 2025-08-26 · How we verify

NCT07130591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficiency of CogniPlat on Cognitive Functions in Older Adults

Completed NA Last updated 26 August 2025

What this trial tests

NA trial testing Cogniplat game platform in Mild Cognitive Impairment in 100 participants. Completed in 15 November 2023.

Timeline

15 January 2023

Primary endpoint
15 May 2023

15 November 2023

Quick facts

Lead sponsor	Izmir Democracy University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	100
Start date	15 January 2023
Primary completion	15 May 2023
Estimated completion	15 November 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Cogniplat game platform
Control group — full drug profile →

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Izmir Democracy University

Who can join

Adults 65 to 78, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mild cognitive impairment is a common intermediate stage between normal aging and dementia, affecting memory and other cognitive domains in older adults. While pharmacologic treatments lack strong evidence, exercise, cognitive training, and game-based interventions have shown positive effects on cognitive functions. The Cogniplat gaming platform, designed to improve cognitive abilities through personalized, multidisciplinary game exercises, has not yet been clinically evaluated. The present study aims to assess the effectiveness of Cogniplat in enhancing cognitive functions in geriatric individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Izmir Democracy University trials

Trials by the same sponsor.

NCT07511153 — Does the Cervical Stenosis Affect Hand Function? · not yet recruiting
NCT07416097 — Comparison of Multidimensional Parameters in Women With Fibromyalgia and Healthy Controls · NA · not yet recruiting
NCT07358702 — Sedentary Status and Multidimensional Outcomes in Fibromyalgia · NA · not yet recruiting
NCT07396597 — Physical Impairments in Premature Ventricular Complex · not yet recruiting
NCT07474623 — Effects of Nicotine Dependence on Multidimensional Health Outcomes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07130591 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Izmir Democracy University
Last refreshed: 26 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07130591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing